GPRC5D CAR T Cells Are Active in BCMA CAR T–Refractory Multiple Myeloma

Article navigation

Research Watch| December 02 2022

Online ISSN: 2159-8290

Print ISSN: 2159-8274

2022

American Association for Cancer Research

Cancer Discov (2022) 12 (12): OF5.

Abstract

GPRC5D-targeted CAR T cells are active in multiple myeloma with a maximum tolerated dose of 150 × 10⁶ cells.

2022

American Association for Cancer Research

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.